TransCode Therapeutics, Inc. RNAZ PHARMA
Company Overview
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -83.69% |
| 6 Months: | -80.46% |
| 3 Months: | -62.87% |
| 1 Month: | -52.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)22.14 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 22 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNAZ TransCode Therapeutics, Inc. PHARMA | 1.89 | -0.04 | $32.00M | 0.00% | -11.27% | -59.28% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.82M | 4.07M | 4.54M | 6.49M | 17.62M |
| Operating Income | - | -91.61K | -239.49K | -449.46K | -355.53K | -2.36M | -3.48M | -4.71M | -4.95M | -4.89M | -5.12M | -5.31M | -3.29M | -5.11M | -2.17M | -2.82M | -4.07M | -4.54M | -6.49M | -17.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.03M | -4.26M | -4.85M | -13.17M | -17.53M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114 | 0 | 5.96K | 542 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.09M | -4.28M | -4.86M | -13.22M | -17.55M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 231.31K |
| Net Income | -41.26K | -127.20K | -1.37M | -4.49M | 2.77M | -2.33M | -3.47M | -4.67M | -4.29M | -4.82M | -4.34M | -5.30M | -3.33M | -5.19M | -2.32M | -12.09M | -4.28M | -4.86M | -13.44M | -17.79M |
| Diluted EPS | - | -0.03 | - | -0.97 | 0.51 | -0.20 | -0.27 | -7.20 | -6.61 | -259.07 | -142.38 | -48.44 | -21.35 | -680.23 | -146.06 | -70.16 | -5.13 | -5.82 | - | -21.28 |
| R&D Expense | - | 75.00K | 53.94K | 263.76K | 211.75K | 992.95K | 1.88M | 2.62M | 3.04M | 2.59M | 2.97M | 3.34M | 1.76M | 3.08M | 1.23M | 2.22M | 2.57M | 3.16M | - | 5.11M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 17.55M | 18.50M | 15.14M | 17.92M |
| Operating Income | -726.60K | - | -17.55M | -18.50M | -15.14M | -17.92M |
| EBITDA | - | - | -17.43M | -17.97M | -16.19M | -34.31M |
| Interest Expense | - | - | 31.99K | 55.90K | 26.81K | 6.62K |
| Pretax Income | - | - | -17.56M | -18.55M | -16.75M | -34.44M |
| Tax Provision | - | - | - | - | 0 | 226.07K |
| Net Income | -2.34M | - | -17.56M | -18.55M | -16.75M | -34.66M |
| Diluted EPS | -0.51 | - | -1,033,233.41 | -27,313.84 | -1,336.63 | -52.59 |
| R&D Expense | 284.46K | 2.75M | 10.23M | 12.26M | 9.71M | 13.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.06M | - | 7.59M | 5.17M | 7.29M | 162.40M |
| Current Assets | - | - | - | 7.38M | 4.46M | 7.09M | 21.98M |
| Cash & Equivalents | - | 828.02K | - | 4.97M | 2.77M | 5.81M | 17.81M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 360.23K | 0 | 0 | 953.10K |
| Total Liabilities | - | 4.46M | - | 4.35M | 3.53M | 9.31M | 10.52M |
| Current Liabilities | - | 404.86K | - | 4.35M | 3.49M | 2.77M | 3.49M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 0 | 450.57K | 38.29K | 0 |
| Total Equity | -1.11M | -3.41M | - | 3.24M | 1.64M | -2.02M | 151.88M |
| Shares Outstanding | - | - | - | 17 | 679 | 36.75K | 916.97K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -492.97K | - | -15.76M | -18.07M | -13.34M | -19.52M |
| Investing Cash Flow | - | - | -100.92K | -35.61K | -21.76K | -4.44K |
| Financing Cash Flow | 1.12M | - | 5.99K | 15.91M | 16.40M | 31.52M |
| Capital Expenditure | - | - | -100.92K | -35.61K | -21.76K | -6.66K |
| Free Cash Flow | - | - | -15.86M | -18.11M | -13.36M | -19.52M |
| Net Change in Cash | - | - | -15.86M | -2.20M | 3.04M | 12.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 68.8% | - | -542.0% | -1,130.3% | 830.0% | -22.8% |
| ROCE % | -111.7% | - | -541.7% | -1,101.5% | -334.7% | -11.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LP | 0.12% | 19.64K | $32.40K |
| 2 | Vanguard Capital Management LLC | 0.04% | 6.54K | $10.80K |
| 3 | Vanguard Fiduciary Trust Co | 0.02% | 2.98K | $4.92K |
| 4 | UBS Group AG | 0.02% | 2.89K | $4.76K |
| 5 | SBI Securities Co., Ltd. | - | 12 | $19 |
| 6 | Tower Research Capital LLC (TRC) | - | 677 | $1.12K |
| 7 | FMR, LLC | - | 706 | $1.16K |
| 8 | Wells Fargo & Company | - | 55 | $90 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNAZ
TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOc0FpS3h5NDlMN01hU0VibXpaWm1pRC02eEN3N3VWUXNtZHdBd1dLdldIdU5nd1psMW9ycmxIVVpmbDlnaHVFcUhudlMwNjVFM1ByWldEWFNPV2xIOXNZWk5TN3lzWjhPcDBVcmVndTFaeFVBLXBGRnpEM1dmVEZoTjJUeVktWUQ4OXY4Rl…
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
<a href="https://news.google.com/rss/articles/CBMilgNBVV95cUxNWE1kQ28wMGt6QnE2RHNROVJjZmNlaU8tZzM3YVdZc1ctWVVCTEdqSnZsZ3dqQ3k3NU1YLWRyakJ0NVZaZmVXbXl3clJYcVN4RkRaX28xOEJIN1ZjLXcyVEV6Z1ExZWxLaVBtNElKVDRDWXhRYldrcG1TNTR2UFNKVm5rT1FWX0ljdXhxWV…
RNAZ - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFA0cWtVNzhXZy1FMUJWNHFrR0diUW1DZi1SV1ZhNWtlM3J0Zl9SWERmYlZhOUxTeE5iUGhsMF9VS2JGWjR1QkE?oc=5" target="_blank">RNAZ</a> <font color="#6f6f6f">Finviz</font>…
TransCode Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAZ) - tradingview.com
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNcFR2dkVPM1BQend6a19Ib1c2TENQdncyRU81SmZ4SVNBM1lYd0tWT2ZPTGRaN0hUNGNhSXRNbzM4MmJBOGZJWXk4NmxzeDIxOXlsUzhaY0JaRVVfV1A2NFduT0pRRE1aNVRHVWhRWmtUQmlEVUFYa3Ayd2VRY1BLcEFFQVdqZw?oc=5" t…
An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNbWxMVjZtLW41Ym9pUDJqaWdxZzhFaDBFX2x0NTFIdHQwNEhZVjQyeWpVNGRpRG40cm1fVk5jOHZwV2tidkpqWlAxZGlYSUFiWm1iNlhLdGk5OURBNHJxR085NG93cl9QQzFUNFJaMGNhRjk3Wjdvb19qMEZQNjJBcFJWWUJnRGg5STkyY0…
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65 - Sector Neutral Pair - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNdmdCcTB6cGdubFJMX09qU1Q3ZFNwQUQ4U19vS2E5bkwwTW1nZGNEckp5YThUQ2hydmxFMHo3WDlMR18yOExTSXdvdUVWUHU5aTM5bFMzMWc1MFlmS0VldDNYaWF0OTRXdmg1TTcyV2tQWXlFSmRpNWhaMTJ0a1puT0t4Wlk1VU9wUnJ2OD…
RNAZ — Frequently Asked Questions
What is the current share price of TransCode Therapeutics, Inc. (RNAZ)?
As of 2026-09-19 21:16 PDT, TransCode Therapeutics, Inc. (RNAZ) trades at $1.89 on NasdaqCM. Its 52-week range is $1.89 to $15.23.
What is the market capitalisation of RNAZ?
TransCode Therapeutics, Inc. (RNAZ) has a market capitalisation of $32.00M on NasdaqCM.
What is the P/E ratio of RNAZ?
RNAZ trades at a trailing price-to-earnings (P/E) ratio of -0.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.06.
What is the return on equity (ROE) of RNAZ?
RNAZ has a return on equity (ROE) of -59.28%. Its return on capital employed (ROCE) is -11.27%.
Is RNAZ a good stock to buy?
This page provides a data-driven analysis of TransCode Therapeutics, Inc. (RNAZ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.